News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celator Pharmaceuticals, Inc. Reaches 75 Percent Enrollment Milestone In Phase 3 Study Of CPX-351


6/4/2014 8:58:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EWING, N.J., June 4, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it has achieved 75% enrollment in the Company's ongoing Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML). The planned enrollment for the study is 300 patients.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES